India vs Philippines: Average cost of multi drug-resistant tuberculosis treatment
India
400 constant 2022 US$
in 2024
Philippines
310 constant 2022 US$
in 2024
India rank
87th
Philippines rank
89th
Average cost of multi drug-resistant tuberculosis treatment over time
- India
- Philippines
How they compare
India currently reports 400 constant 2022 US$ against 310 constant 2022 US$ in Philippines, a difference of 90 constant 2022 US$.
That makes India's figure about 1.3 times Philippines's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Philippines ahead.
India ranks 87th and Philippines ranks 89th of 92 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,700 constant 2022 US$ | 4,921 constant 2022 US$ | 3,221 constant 2022 US$ | Philippines |
| 2020s | 444.2 constant 2022 US$ | 1.36 million constant 2022 US$ | 1.35 million constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, India or Philippines?
- India, at 400 constant 2022 US$ against 310 constant 2022 US$ in Philippines as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between India and Philippines?
- 90 constant 2022 US$, with India ahead.
- How many years of comparable data are there for India and Philippines?
- 8 years are reported by both, from 2017 to 2024.
- How do India and Philippines rank globally for average cost of multi drug-resistant tuberculosis treatment?
- India ranks 87th and Philippines ranks 89th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.